Details for Patent: 12,734,126
Which drugs does patent 12,734,126 protect, and when does it expire?
Patent 12,734,126 protects RYZUMVI and is included in one NDA.
This patent has ten patent family members in eight countries.
Drugs Protected by US Patent 12,734,126
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 12,734,126 | ⤷ Start Trial | A METHOD OF PUPIL REDUCTION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,734,126
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014212274 | ⤷ Start Trial | |||
| Australia | 2018200566 | ⤷ Start Trial | |||
| Canada | 2899339 | ⤷ Start Trial | |||
| Denmark | 2950648 | ⤷ Start Trial | |||
| European Patent Office | 2950648 | ⤷ Start Trial | |||
| Spain | 2762153 | ⤷ Start Trial | |||
| Japan | 2016506966 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
